Why Anticholinergic Medications Are Not Recommended for Elderly Patients
Anticholinergic medications should be routinely evaluated and deprescribed in older adults because they cause cumulative cognitive impairment, delirium, falls, functional decline, and potentially death—risks that are disproportionately severe in this population due to age-related physiological changes and polypharmacy. 1, 2
The Core Problem: Cumulative Anticholinergic Burden
The fundamental issue is not just individual anticholinergic drugs, but the cumulative anticholinergic burden—the additive effect when multiple medications with anticholinergic properties are used together. This is particularly dangerous because one-third to one-half of medications commonly prescribed to older adults have some degree of anticholinergic activity 3. Even medications with modest antimuscarinic activity can accumulate to cause significant harm 4.
Why Elderly Patients Are Uniquely Vulnerable
Older adults experience several physiological changes that amplify anticholinergic toxicity:
- Baseline cholinergic deficits: Many elderly patients already have age-related cognitive impairment or underlying cholinergic system dysfunction 4
- Altered pharmacokinetics and pharmacodynamics: Age-related changes in drug metabolism and receptor sensitivity increase susceptibility to adverse effects 5
- Polypharmacy: Multiple medications create drug-drug interactions that heighten anticholinergic effects 5
- Pre-existing conditions: Comorbidities like dementia, Parkinson's disease, and urinary retention make patients more susceptible to anticholinergic toxicity 6
Specific Harms in the Elderly
Cognitive and Neuropsychiatric Effects
The central nervous system effects range from subtle to catastrophic:
- Cognitive impairment and inability to concentrate
- Delirium (acute confusion)
- Sedation and drowsiness
- Increased risk of dementia with long-term exposure 4, 7
These effects are often mistakenly attributed to "normal aging" rather than recognized as medication-induced and potentially reversible 5.
Physical and Functional Consequences
Peripheral anticholinergic effects that seem minor in younger patients become dangerous in the elderly:
- Falls risk: Blurred vision, sedation, and orthostatic effects directly increase fall risk 1, 7
- Cardiovascular: Tachycardia can precipitate or worsen angina 5
- Urinary retention: Particularly problematic in men with prostatic hypertrophy 5
- Constipation and fecal impaction: Can lead to serious complications 5, 8
- Dry mouth: Predisposes to malnutrition, dental problems, and respiratory infections due to loss of antimicrobial saliva activity 5
- Thermoregulatory failure: Inability to sweat can cause life-threatening hyperthermia 5
- Vision impairment: Can precipitate narrow-angle glaucoma and increase accident risk 5
Mortality Risk
The 2019 AGS Beers Criteria explicitly identifies anticholinergics as contributing to death in older adults 1.
Clinical Action Algorithm
Step 1: Identify Total Anticholinergic Burden
Use a validated anticholinergic burden scale to quantify cumulative exposure:
- Anticholinergic Cognitive Burden (ACB) scale
- Anticholinergic Risk Scale (ARS)
- Anticholinergic Drug Scale (ADS) 7, 9
High-risk threshold: ACB score ≥3 10
Step 2: Systematically Review the Medication List
The 2026 consensus guidelines mandate that medication lists of older adults should be routinely evaluated for cumulative anticholinergic burden, and collaborative efforts should be made to discontinue or reduce medications with substantial anticholinergic activity 2.
Look specifically for:
- Tricyclic antidepressants (TCAs)
- First-generation antihistamines
- Antipsychotics
- Urinary antispasmodics
- Antiparkinson agents
- H2-receptor antagonists 1
Common high-risk drugs include amitriptyline, chlorpromazine, imipramine, paroxetine, and promethazine 9.
Step 3: Identify High-Risk Patients Requiring Immediate Action
Prioritize deprescribing in patients with:
- History of falls or fractures
- Cognitive impairment or dementia
- Delirium
- Orthostatic hypotension
- Multiple medications (polypharmacy)
- Depression or psychiatric disorders 1, 2, 6
Step 4: Deprescribe or Switch to Lower-Risk Alternatives
Where clinically feasible, discontinue anticholinergic medications or switch to alternatives with lower anticholinergic activity 2, 3.
For example:
- For OAB: Consider beta-3 agonists instead of anticholinergics (though cost barriers exist) 10
- For depression: Switch from TCAs or paroxetine to SSRIs/SNRIs with lower anticholinergic profiles
- For allergies: Use second-generation antihistamines
Step 5: Check for Drug-Drug Interactions Before Deprescribing
Before removing any medication, comprehensively check for drug-drug interactions (especially cytochrome P450 substrates) that might be affected by elimination of the anticholinergic drug 2. This is critical in medically complex older adults.
Critical Caveats
The Evidence Has Nuances
While observational studies consistently show associations between anticholinergic burden and adverse outcomes (delirium, falls, functional decline), findings regarding long-term cognitive decline and dementia remain inconsistent and vary by drug class and burden scale used 7. However, this uncertainty should not prevent action—the short-term harms (delirium, falls, drowsiness) are well-established and clinically significant 7.
Individual Risk-Benefit Still Matters
The 2019 AGS Beers Criteria acknowledges that in patients with complex treatment histories and limited alternatives, the decision to deprescribe must be weighed against the lack of better options 2. However, this should be the exception, not the rule.
Common Pitfall: Attributing Symptoms to Aging
The most dangerous error is dismissing anticholinergic symptoms as "normal aging" 5. Dry mouth, mild confusion, constipation, and urinary hesitancy are often drug-induced and reversible, not inevitable consequences of age.
Monitoring After Deprescribing
When anticholinergics are stopped, monitor for:
- Improvement in cognitive function
- Reduced fall risk
- Resolution of peripheral symptoms
- Potential withdrawal effects or disease recurrence requiring alternative management
Special Populations
Patients with depression or psychiatric disorders are at particularly high risk for inappropriate anticholinergic use, as these conditions are strongly associated with anticholinergic prescribing 6. These patients require especially careful medication review.
Women with overactive bladder: 37% have high-risk baseline ACB scores before any OAB treatment is initiated, and 71% of those prescribed anticholinergics for OAB already have high-risk scores 10. This population requires alternative first-line therapies.